HC Wainwright Lowers Earnings Estimates for BridgeBio Pharma

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Equities research analysts at HC Wainwright decreased their Q1 2025 earnings per share estimates for BridgeBio Pharma in a note issued to investors on Tuesday, April 15th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($1.01) for the quarter, down from their previous estimate of ($0.83). HC Wainwright has a “Buy” rating and a $53.00 price target on the stock. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($3.67) per share. HC Wainwright also issued estimates for BridgeBio Pharma’s Q2 2025 earnings at ($1.08) EPS, Q3 2025 earnings at ($1.02) EPS, Q4 2025 earnings at ($1.06) EPS, FY2025 earnings at ($4.17) EPS and Q1 2026 earnings at ($0.85) EPS.

A number of other equities analysts have also recently issued reports on the stock. Redburn Atlantic assumed coverage on BridgeBio Pharma in a report on Monday, March 31st. They set a “buy” rating and a $50.00 target price for the company. Evercore ISI lifted their target price on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the company an “outperform” rating in a research note on Monday, December 23rd. Cantor Fitzgerald reiterated an “overweight” rating and set a $95.00 price target on shares of BridgeBio Pharma in a research report on Friday, February 21st. Scotiabank lifted their price objective on BridgeBio Pharma from $49.00 to $52.00 and gave the company a “sector outperform” rating in a research report on Friday, February 21st. Finally, Citigroup upped their target price on BridgeBio Pharma from $45.00 to $49.00 and gave the stock a “buy” rating in a report on Friday, February 21st. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, BridgeBio Pharma presently has a consensus rating of “Moderate Buy” and a consensus price target of $53.00.

BridgeBio Pharma Price Performance

Shares of BBIO stock opened at $33.87 on Thursday. The business has a 50-day moving average of $33.73 and a 200 day moving average of $30.01. The stock has a market capitalization of $6.44 billion, a PE ratio of -11.88 and a beta of 1.08. BridgeBio Pharma has a 1-year low of $21.62 and a 1-year high of $39.47.

BridgeBio Pharma (NASDAQ:BBIO) last released its quarterly earnings results on Thursday, February 20th. The company reported ($1.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.22). The business had revenue of $5.88 million during the quarter, compared to analyst estimates of $4.04 million.

Insider Transactions at BridgeBio Pharma

In related news, CFO Brian C. Stephenson sold 4,148 shares of the stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $36.16, for a total transaction of $149,991.68. Following the transaction, the chief financial officer now owns 102,464 shares in the company, valued at $3,705,098.24. This represents a 3.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Andrea Ellis sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $35.00, for a total transaction of $350,000.00. Following the completion of the sale, the director now owns 12,000 shares in the company, valued at $420,000. This represents a 45.45 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 9,694,739 shares of company stock worth $327,308,651 over the last quarter. 24.66% of the stock is currently owned by insiders.

Hedge Funds Weigh In On BridgeBio Pharma

Several institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its holdings in BridgeBio Pharma by 6.2% during the fourth quarter. Vanguard Group Inc. now owns 15,077,915 shares of the company’s stock valued at $413,738,000 after purchasing an additional 879,059 shares during the period. Janus Henderson Group PLC grew its stake in shares of BridgeBio Pharma by 1.9% during the 4th quarter. Janus Henderson Group PLC now owns 4,907,533 shares of the company’s stock valued at $134,672,000 after acquiring an additional 89,521 shares during the period. Farallon Capital Management LLC increased its holdings in BridgeBio Pharma by 140.1% in the 4th quarter. Farallon Capital Management LLC now owns 4,195,000 shares of the company’s stock worth $115,111,000 after acquiring an additional 2,448,000 shares in the last quarter. Frazier Life Sciences Management L.P. raised its stake in BridgeBio Pharma by 1.1% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 3,800,457 shares of the company’s stock worth $104,285,000 after acquiring an additional 40,000 shares during the period. Finally, Capital Research Global Investors lifted its holdings in BridgeBio Pharma by 34.9% during the fourth quarter. Capital Research Global Investors now owns 3,526,747 shares of the company’s stock valued at $96,774,000 after purchasing an additional 912,439 shares in the last quarter. Institutional investors own 99.85% of the company’s stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.